Trial Outcomes & Findings for Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis (NCT NCT03903822)

Last Updated: 2021-03-29

Results Overview

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

292 participants

Primary outcome timeframe

Baseline, Week 6

Results posted on

2021-03-29

Participant Flow

Participant milestones

Participant milestones
Measure	Vehicle Cream Once Daily (QD) Participants or caregivers of participants, topically applied vehicle cream on all eligible atopic dermatitis (AD) areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD Participants or caregivers of participants, topically applied PF-06700841 0.1 percent (%) cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Treatment Phase (6 Weeks) STARTED	37	37	36	37	36	36	36	37
Treatment Phase (6 Weeks) COMPLETED	28	27	33	32	31	25	31	33
Treatment Phase (6 Weeks) NOT COMPLETED	9	10	3	5	5	11	5	4
Follow up Phase (4 Weeks) STARTED	37	37	36	37	36	36	36	37
Follow up Phase (4 Weeks) COMPLETED	29	29	32	33	32	28	31	31
Follow up Phase (4 Weeks) NOT COMPLETED	8	8	4	4	4	8	5	6

Reasons for withdrawal

Reasons for withdrawal
Measure	Vehicle Cream Once Daily (QD) Participants or caregivers of participants, topically applied vehicle cream on all eligible atopic dermatitis (AD) areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD Participants or caregivers of participants, topically applied PF-06700841 0.1 percent (%) cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Treatment Phase (6 Weeks) Adverse Event	3	3	1	1	1	6	1	0
Treatment Phase (6 Weeks) Lack of Efficacy	0	0	0	0	1	1	0	0
Treatment Phase (6 Weeks) Lost to Follow-up	0	0	0	0	0	0	1	1
Treatment Phase (6 Weeks) Physician Decision	0	2	0	0	0	0	0	0
Treatment Phase (6 Weeks) Pregnancy	0	0	0	1	1	0	0	0
Treatment Phase (6 Weeks) Protocol Violation	0	0	0	1	0	0	0	0
Treatment Phase (6 Weeks) Withdrawal by Subject	2	4	2	2	1	2	3	3
Treatment Phase (6 Weeks) Refused Further Treatment	2	0	0	0	0	1	0	0
Treatment Phase (6 Weeks) Other	2	1	0	0	1	1	0	0
Follow up Phase (4 Weeks) Adverse Event	3	2	1	1	0	5	1	0
Follow up Phase (4 Weeks) Lack of Efficacy	0	0	0	0	1	0	0	0
Follow up Phase (4 Weeks) Lost to Follow-up	2	0	0	0	0	0	1	3
Follow up Phase (4 Weeks) Pregnancy	0	0	0	1	1	0	0	0
Follow up Phase (4 Weeks) Withdrawal by Subject	2	5	3	2	2	2	3	3
Follow up Phase (4 Weeks) Refused Further Study Procedures	0	0	0	0	0	1	0	0
Follow up Phase (4 Weeks) Other	1	1	0	0	0	0	0	0

Baseline Characteristics

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Total n=292 Participants Total of all reporting groups
Age, Continuous	39.1 Years STANDARD_DEVIATION 16.80 • n=5 Participants	40.8 Years STANDARD_DEVIATION 15.35 • n=7 Participants	43.4 Years STANDARD_DEVIATION 16.43 • n=5 Participants	38.4 Years STANDARD_DEVIATION 12.90 • n=4 Participants	40.5 Years STANDARD_DEVIATION 12.30 • n=21 Participants	42.3 Years STANDARD_DEVIATION 18.18 • n=8 Participants	39.4 Years STANDARD_DEVIATION 17.27 • n=8 Participants	38.1 Years STANDARD_DEVIATION 15.34 • n=24 Participants	40.2 Years STANDARD_DEVIATION 15.59 • n=42 Participants
Sex: Female, Male Female	20 Participants n=5 Participants	19 Participants n=7 Participants	24 Participants n=5 Participants	23 Participants n=4 Participants	15 Participants n=21 Participants	19 Participants n=8 Participants	16 Participants n=8 Participants	20 Participants n=24 Participants	156 Participants n=42 Participants
Sex: Female, Male Male	17 Participants n=5 Participants	18 Participants n=7 Participants	12 Participants n=5 Participants	14 Participants n=4 Participants	21 Participants n=21 Participants	17 Participants n=8 Participants	20 Participants n=8 Participants	17 Participants n=24 Participants	136 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=8 Participants	0 Participants n=8 Participants	4 Participants n=24 Participants	13 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	37 Participants n=5 Participants	37 Participants n=7 Participants	32 Participants n=5 Participants	35 Participants n=4 Participants	35 Participants n=21 Participants	33 Participants n=8 Participants	35 Participants n=8 Participants	33 Participants n=24 Participants	277 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	0 Participants n=24 Participants	2 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	4 Participants n=5 Participants	8 Participants n=7 Participants	4 Participants n=5 Participants	8 Participants n=4 Participants	10 Participants n=21 Participants	9 Participants n=8 Participants	9 Participants n=8 Participants	7 Participants n=24 Participants	59 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	2 Participants n=42 Participants
Race (NIH/OMB) Black or African American	8 Participants n=5 Participants	7 Participants n=7 Participants	9 Participants n=5 Participants	6 Participants n=4 Participants	4 Participants n=21 Participants	6 Participants n=8 Participants	5 Participants n=8 Participants	6 Participants n=24 Participants	51 Participants n=42 Participants
Race (NIH/OMB) White	24 Participants n=5 Participants	22 Participants n=7 Participants	21 Participants n=5 Participants	20 Participants n=4 Participants	21 Participants n=21 Participants	20 Participants n=8 Participants	22 Participants n=8 Participants	24 Participants n=24 Participants	174 Participants n=42 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	5 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants

PRIMARY outcome

Timeframe: Baseline, Week 6

Population: Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method assuming responses are similar to the corresponding vehicle arm under the MAR assumption

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation	-44.4 Percent change Interval -57.3 to -31.6	-58.3 Percent change Interval -71.2 to -45.5	-64.6 Percent change Interval -77.1 to -52.1	-70.1 Percent change Interval -82.1 to -58.0	-67.9 Percent change Interval -80.6 to -55.3	-47.6 Percent change Interval -57.5 to -37.7	-58.6 Percent change Interval -67.5 to -49.7	-75.0 Percent change Interval -83.8 to -66.2

SECONDARY outcome

Timeframe: Baseline, Week 6

Population: Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Non-Responder Imputation (NRI) method: participants with missing values were considered to be non-responders.

IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 6: Non-responder Imputation	10.8 Percentage of participants Interval 4.8 to 22.2	29.7 Percentage of participants Interval 18.5 to 43.3	33.3 Percentage of participants Interval 21.3 to 47.0	40.5 Percentage of participants Interval 28.0 to 54.4	44.4 Percentage of participants Interval 30.2 to 59.1	13.9 Percentage of participants Interval 6.9 to 25.4	33.3 Percentage of participants Interval 21.3 to 47.0	27.0 Percentage of participants Interval 15.5 to 40.2

SECONDARY outcome

Timeframe: Baseline, Week 6

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation	-3.2 Units on a scale Interval -4.1 to -2.3	-4.5 Units on a scale Interval -5.4 to -3.6	-4.6 Units on a scale Interval -5.5 to -3.7	-4.8 Units on a scale Interval -5.7 to -3.9	-5.5 Units on a scale Interval -6.4 to -4.7	-3.6 Units on a scale Interval -4.3 to -3.0	-4.4 Units on a scale Interval -5.0 to -3.8	-5.3 Units on a scale Interval -5.9 to -4.7

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 2, 3, 4 and 6

Population: Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. NRI method: participants with missing values were considered to be non-responders.

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 3	21.6 Percentage of participants Interval 11.2 to 34.3	38.9 Percentage of participants Interval 25.4 to 53.0	48.6 Percentage of participants Interval 33.8 to 63.5	59.5 Percentage of participants Interval 45.6 to 72.0	58.3 Percentage of participants Interval 44.0 to 71.0	33.3 Percentage of participants Interval 21.3 to 47.0	51.4 Percentage of participants Interval 36.5 to 66.2	57.1 Percentage of participants Interval 41.9 to 70.0
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 4	35.1 Percentage of participants Interval 22.2 to 49.3	38.9 Percentage of participants Interval 25.4 to 53.0	51.4 Percentage of participants Interval 36.5 to 66.2	62.2 Percentage of participants Interval 48.0 to 75.2	58.3 Percentage of participants Interval 44.0 to 71.0	30.6 Percentage of participants Interval 18.9 to 44.0	60.0 Percentage of participants Interval 44.8 to 74.0	60.0 Percentage of participants Interval 44.8 to 74.0
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 6	40.5 Percentage of participants Interval 28.0 to 54.4	41.7 Percentage of participants Interval 29.0 to 56.0	51.4 Percentage of participants Interval 36.5 to 66.2	56.8 Percentage of participants Interval 43.2 to 70.7	61.1 Percentage of participants Interval 47.0 to 74.6	30.6 Percentage of participants Interval 18.9 to 44.0	60.0 Percentage of participants Interval 44.8 to 74.0	60.0 Percentage of participants Interval 44.8 to 74.0
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 1	16.2 Percentage of participants Interval 7.3 to 29.3	16.7 Percentage of participants Interval 7.5 to 30.2	20.0 Percentage of participants Interval 11.0 to 33.8	29.7 Percentage of participants Interval 18.5 to 43.3	44.4 Percentage of participants Interval 30.2 to 59.1	13.9 Percentage of participants Interval 6.9 to 25.4	28.6 Percentage of participants Interval 16.4 to 41.9	25.7 Percentage of participants Interval 15.4 to 39.2
Percentage of Participants Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 2	24.3 Percentage of participants Interval 14.5 to 37.0	30.6 Percentage of participants Interval 18.9 to 44.0	42.9 Percentage of participants Interval 30.0 to 58.1	48.6 Percentage of participants Interval 34.3 to 63.0	61.1 Percentage of participants Interval 47.0 to 74.6	25.0 Percentage of participants Interval 14.9 to 38.0	45.7 Percentage of participants Interval 31.7 to 60.8	37.1 Percentage of participants Interval 23.6 to 52.2

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=33 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=30 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=32 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=31 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=28 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=30 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=30 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=27 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation At Week 1	0.0 Percentage of participants Interval 0.0 to 8.2	3.3 Percentage of participants Interval 0.4 to 14.0	3.1 Percentage of participants Interval 0.3 to 13.1	16.1 Percentage of participants Interval 8.1 to 29.7	10.7 Percentage of participants Interval 4.0 to 23.8	3.3 Percentage of participants Interval 0.4 to 14.0	3.3 Percentage of participants Interval 0.4 to 14.0	11.1 Percentage of participants Interval 4.2 to 24.8
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation At Week 2	9.1 Percentage of participants Interval 3.4 to 20.2	10.0 Percentage of participants Interval 3.7 to 22.1	9.4 Percentage of participants Interval 3.5 to 20.7	19.4 Percentage of participants Interval 8.8 to 32.7	25.0 Percentage of participants Interval 13.9 to 40.0	10.0 Percentage of participants Interval 3.7 to 22.1	13.3 Percentage of participants Interval 5.9 to 27.9	33.3 Percentage of participants Interval 20.4 to 50.0
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation At Week 3	12.1 Percentage of participants Interval 5.4 to 25.1	23.3 Percentage of participants Interval 12.9 to 37.6	15.6 Percentage of participants Interval 7.8 to 28.7	32.3 Percentage of participants Interval 18.7 to 48.2	32.1 Percentage of participants Interval 19.7 to 47.3	10.0 Percentage of participants Interval 3.7 to 22.1	20.0 Percentage of participants Interval 9.1 to 33.9	37.0 Percentage of participants Interval 22.1 to 54.7
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation At Week 4	18.2 Percentage of participants Interval 8.2 to 31.3	26.7 Percentage of participants Interval 14.0 to 41.6	28.1 Percentage of participants Interval 17.0 to 43.3	35.5 Percentage of participants Interval 21.3 to 51.8	50.0 Percentage of participants Interval 33.3 to 66.7	10.0 Percentage of participants Interval 3.7 to 22.1	30.0 Percentage of participants Interval 18.2 to 45.5	37.0 Percentage of participants Interval 22.1 to 54.7
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation At Week 6	18.2 Percentage of participants Interval 8.2 to 31.3	30.0 Percentage of participants Interval 18.2 to 45.5	34.4 Percentage of participants Interval 20.7 to 50.0	45.2 Percentage of participants Interval 29.7 to 60.1	50.0 Percentage of participants Interval 33.3 to 66.7	16.7 Percentage of participants Interval 8.3 to 30.8	33.3 Percentage of participants Interval 19.3 to 49.2	40.7 Percentage of participants Interval 24.8 to 58.3
Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation At Follow-up visit	9.1 Percentage of participants Interval 3.4 to 20.2	30.0 Percentage of participants Interval 18.2 to 45.5	21.9 Percentage of participants Interval 12.1 to 36.2	19.4 Percentage of participants Interval 8.8 to 32.7	21.4 Percentage of participants Interval 9.8 to 36.6	20.0 Percentage of participants Interval 9.1 to 33.9	20.0 Percentage of participants Interval 9.1 to 33.9	7.4 Percentage of participants Interval 2.0 to 20.4

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

Population: Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure and "number analyzed" signifies participants evaluable for the each specified time point.

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=34 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=33 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=34 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=34 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit At Week 1	-2.4 Percent change Interval -12.2 to 7.4	-2.9 Percent change Interval -12.5 to 6.8	-16.2 Percent change Interval -26.2 to -6.2	-19.9 Percent change Interval -29.6 to -10.2	-23.0 Percent change Interval -32.8 to -13.1	8.5 Percent change Interval -8.3 to 25.3	-16.5 Percent change Interval -32.9 to -0.1	-17.0 Percent change Interval -33.5 to -0.5
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit At Week 2	-15.3 Percent change Interval -28.0 to -2.6	-7.2 Percent change Interval -20.2 to 5.8	-38.1 Percent change Interval -51.0 to -25.2	-43.6 Percent change Interval -56.5 to -30.8	-39.0 Percent change Interval -52.1 to -26.0	-2.5 Percent change Interval -14.0 to 9.1	-34.2 Percent change Interval -45.4 to -22.9	-43.1 Percent change Interval -54.5 to -31.6
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit At Week 3	-17.1 Percent change Interval -31.0 to -3.1	-13.1 Percent change Interval -27.4 to 1.1	-50.6 Percent change Interval -64.4 to -36.7	-55.9 Percent change Interval -69.7 to -42.0	-49.2 Percent change Interval -63.2 to -35.1	-25.2 Percent change Interval -39.2 to -11.1	-39.8 Percent change Interval -53.0 to -26.6	-44.0 Percent change Interval -57.1 to -30.9
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit At Week 4	-25.9 Percent change Interval -39.8 to -12.0	-20.1 Percent change Interval -34.4 to -5.7	-55.8 Percent change Interval -69.5 to -42.1	-57.9 Percent change Interval -71.7 to -44.0	-56.7 Percent change Interval -70.8 to -42.7	-34.7 Percent change Interval -46.1 to -23.3	-46.4 Percent change Interval -56.9 to -35.9	-57.7 Percent change Interval -68.2 to -47.2
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit At Week 6	-21.6 Percent change Interval -38.0 to -5.3	-39.4 Percent change Interval -56.1 to -22.7	-59.4 Percent change Interval -75.4 to -43.5	-63.6 Percent change Interval -79.5 to -47.6	-60.3 Percent change Interval -76.4 to -44.1	-31.2 Percent change Interval -42.5 to -20.0	-48.9 Percent change Interval -59.3 to -38.6	-65.0 Percent change Interval -75.3 to -54.7
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit At Follow-up visit	-23.6 Percent change Interval -39.5 to -7.6	-24.5 Percent change Interval -41.0 to -8.0	-42.7 Percent change Interval -58.1 to -27.2	-37.0 Percent change Interval -52.6 to -21.4	-55.2 Percent change Interval -71.8 to -38.6	-26.3 Percent change Interval -47.5 to -5.2	-31.6 Percent change Interval -52.0 to -11.3	-24.6 Percent change Interval -45.2 to -4.1

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 2, 3, 4 and 6

Population: Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. NRI method: participants with missing values were considered to be non-responders.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 1	5.4 Percentage of participants Interval 1.4 to 15.5	0.0 Percentage of participants Interval 0.0 to 7.3	19.4 Percentage of participants Interval 10.7 to 32.8	5.4 Percentage of participants Interval 1.4 to 15.5	16.7 Percentage of participants Interval 7.5 to 30.2	0.0 Percentage of participants Interval 0.0 to 7.5	13.9 Percentage of participants Interval 6.9 to 25.4	21.6 Percentage of participants Interval 11.2 to 34.3
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 2	8.1 Percentage of participants Interval 3.0 to 18.5	10.8 Percentage of participants Interval 4.8 to 22.2	27.8 Percentage of participants Interval 15.9 to 40.9	24.3 Percentage of participants Interval 14.5 to 37.0	38.9 Percentage of participants Interval 25.4 to 53.0	13.9 Percentage of participants Interval 6.9 to 25.4	25.0 Percentage of participants Interval 14.9 to 38.0	32.4 Percentage of participants Interval 20.6 to 46.4
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 3	5.4 Percentage of participants Interval 1.4 to 15.5	16.2 Percentage of participants Interval 7.3 to 29.3	36.1 Percentage of participants Interval 22.9 to 50.0	43.2 Percentage of participants Interval 29.3 to 56.8	41.7 Percentage of participants Interval 29.0 to 56.0	19.4 Percentage of participants Interval 10.7 to 32.8	19.4 Percentage of participants Interval 10.7 to 32.8	43.2 Percentage of participants Interval 29.3 to 56.8
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 4	24.3 Percentage of participants Interval 14.5 to 37.0	21.6 Percentage of participants Interval 11.2 to 34.3	38.9 Percentage of participants Interval 25.4 to 53.0	43.2 Percentage of participants Interval 29.3 to 56.8	50.0 Percentage of participants Interval 35.3 to 64.7	22.2 Percentage of participants Interval 11.6 to 35.3	36.1 Percentage of participants Interval 22.9 to 50.0	48.6 Percentage of participants Interval 34.3 to 63.0
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation At Week 6	35.1 Percentage of participants Interval 22.2 to 49.3	32.4 Percentage of participants Interval 20.6 to 46.4	52.8 Percentage of participants Interval 38.0 to 67.2	54.1 Percentage of participants Interval 40.2 to 68.2	50.0 Percentage of participants Interval 35.3 to 64.7	16.7 Percentage of participants Interval 7.5 to 30.2	36.1 Percentage of participants Interval 22.9 to 50.0	51.4 Percentage of participants Interval 37.0 to 65.7

SECONDARY outcome

Timeframe: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

Population: Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) TEAEs	18 Participants	17 Participants	11 Participants	12 Participants	10 Participants	17 Participants	9 Participants	14 Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) SAEs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline up to Week 6

Population: Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure and "number analyzed" signifies participants evaluable for the each specified time point.

Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of \>= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of \>=20mmHg decrease, c) supine DBP: less than (\<) 50 mmHg, d) supine DBP: change of \>= 20mmHg increase, e) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: \<90 mmHg, b) sitting SBP: change of \>=30mmHg increase, c) sitting SBP: change of \>=30mmHg decrease, d) supine SBP: change of \>=30mmHg increase, e) supine SBP: change of \>=30mmHg decrease and f) Supine SBP: value \<90mmHg.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=21 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=20 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=25 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=18 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=21 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=19 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=22 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=22 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Number of Participants With Pre-defined Criteria For Vital Signs Sitting SBP: change >= 30mmHg decrease	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Supine SBP: Change >= 30mmHg increase	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Supine SBP: Change >= 30mmHg decrease	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Supine SBP: Value <90mmHg	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Sitting SBP: change >= 30mmHg increase	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Sitting DBP: Change >= 20 mm Hg increase	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Sitting DBP: Change >= 20mmHg decrease	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Supine DBP: Value <50 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Supine DBP: Change >= 20mmHg increase	0 Participants	1 Participants	1 Participants	2 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Supine DBP: Change >= 20mmHg decrease	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Pre-defined Criteria For Vital Signs Sitting SBP: <90mmHg	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)\<0.8\*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)\<0.5\*LLN,\>1.5\*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate\<0.9\*LLN,\>1.1\*ULN;platelets\<0.5\*LLN,\>1.75\*ULN;leukocytes (leu.),glucose\<0.6\*LLN,\>1.5\*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin \<0.8\*LLN,\>1.2\*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate \>1.2\*ULN;bilirubin (total, direct, indirect)\>1.5\*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase\>3.0\*ULN;urea nitrogen, creatinine, triglycerides, chl.\>1.3\*ULN; sodium \<0.95\*LLN,\>1.05\*ULN; creatine kinase \>2.0\*ULN;Urine: pH\<4.5,\>8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase\>=1;ery., leu.\>= 20;hyaline casts\>1;bacteria\>20.

Outcome measures

Outcome measures
Measure	Vehicle Cream Once Daily (QD) n=37 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.1% Cream QD n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream QD n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream QD n=37 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 3.0% Cream QD n=35 Participants Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	Vehicle Cream Twice Daily (BID) n=36 Participants Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 0.3% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.	PF-06700841 1.0% Cream BID n=36 Participants Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.
Number of Participants With Laboratory Abnormalities	26 Participants	22 Participants	23 Participants	22 Participants	16 Participants	21 Participants	24 Participants	24 Participants

SECONDARY outcome

Timeframe: Baseline up to Week 6

Clinically significant ECG criteria included PR interval: value greater than (\>) 280 millisecond (msec), percentage change greater than equal to (\>=) 25/50 percentage, QRS interval: value \>120 msec, percentage change \>= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30\<=change\<60.